Ultragenyx Pharmaceutical (RARE) to Release Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.30) per share and revenue of $199.5960 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $23.88 on Tuesday. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $46.27. The firm has a market cap of $2.30 billion, a P/E ratio of -4.02 and a beta of 0.16. The business’s 50 day moving average price is $27.93 and its 200-day moving average price is $29.89.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,061 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares in the company, valued at $2,095,308.60. The trade was a 3.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 6,227 shares of company stock worth $187,126 over the last ninety days. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. lifted its holdings in Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the period. Wellington Management Group LLP lifted its holdings in Ultragenyx Pharmaceutical by 3.9% during the third quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company’s stock valued at $58,509,000 after purchasing an additional 73,309 shares in the last quarter. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 16.3% in the 4th quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after buying an additional 257,701 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Ultragenyx Pharmaceutical by 0.6% during the second quarter. Alliancebernstein L.P. now owns 1,255,203 shares of the biopharmaceutical company’s stock valued at $45,639,000 after acquiring an additional 7,823 shares during the period. Finally, Schonfeld Strategic Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 101.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,144,589 shares of the biopharmaceutical company’s stock valued at $34,429,000 after acquiring an additional 577,414 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx’s gene therapy shows long‑term efficacy in two Sanfilippo studies — supports durability of clinical benefit and strengthens the therapy’s commercial/clinical case, a medium/long‑term positive for RARE. BioSpace Article
• Neutral Sentiment: Quant snapshot placed Ultragenyx among lagging names in a market buy/sell screen — indicates short‑term positioning flows but not a new company-specific development. MSN Quant Snapshot
• Negative Sentiment: Multiple plaintiff firms have filed or posted notices about a class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are soliciting lead plaintiffs (lead‑plaintiff deadline April 6, 2026). The surge of filings/solicitations (Rosen Law, Faruqi & Faruqi, Robbins LLP, DJS Law Group, Schall Law Firm, Bronstein Gewirtz & Grossman, etc.) increases legal risk, potential settlement exposure, and creates investor uncertainty/near‑term selling pressure. Links: Rosen Law release Rosen Law, Faruqi & Faruqi notice Faruqi, Robbins LLP reminder Robbins LLP, DJS Law Group notice DJS, Schall Law Firm Schall, Bronstein notice Bronstein.

Wall Street Analyst Weigh In

RARE has been the topic of several recent analyst reports. Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Leerink Partners cut their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Truist Financial decreased their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. TD Cowen lowered their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Guggenheim decreased their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.